Cargando…
Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review
Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distress syndrome (ARDS) as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388062/ https://www.ncbi.nlm.nih.gov/pubmed/32867652 http://dx.doi.org/10.2174/1566523220999200820172829 |
_version_ | 1783742568367915008 |
---|---|
author | Li, Jingwen Wang, Xinyi Li, Na Jiang, Ying Huang, Heqing Wang, Tao Lin, Zhicheng Xiong, Nian |
author_facet | Li, Jingwen Wang, Xinyi Li, Na Jiang, Ying Huang, Heqing Wang, Tao Lin, Zhicheng Xiong, Nian |
author_sort | Li, Jingwen |
collection | PubMed |
description | Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distress syndrome (ARDS) as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients with complications such as cytokine storm syndrome (CSS), who have a high fatality rate. Neither specific anti-SARS-CoV-2 drugs nor vaccines exist currently. Current treatment relies mainly on self-recovery through patients' immune function. Mesenchymal stem cells (MSCs) is a kind of multipotent tissue stem cells, which have powerful anti-inflammatory and immune regulatory functions, inhibiting the cytokine storms. In addition, MSCs have a strong ability to repair tissue damage and reduce the risk of severe complications such as acute lung injury and ARDS, and hopefully, reduce the fatality rate in these patients. There are several clinical types of research completed for treating COVID-19 with MSCs, all reporting restoration of T cells and clinical safety. Here we discuss the clinical prospect and conclude the therapeutic effects and potential mechanism for MSCs in treating COVID-19. |
format | Online Article Text |
id | pubmed-8388062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-83880622021-09-07 Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review Li, Jingwen Wang, Xinyi Li, Na Jiang, Ying Huang, Heqing Wang, Tao Lin, Zhicheng Xiong, Nian Curr Gene Ther Article Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distress syndrome (ARDS) as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients with complications such as cytokine storm syndrome (CSS), who have a high fatality rate. Neither specific anti-SARS-CoV-2 drugs nor vaccines exist currently. Current treatment relies mainly on self-recovery through patients' immune function. Mesenchymal stem cells (MSCs) is a kind of multipotent tissue stem cells, which have powerful anti-inflammatory and immune regulatory functions, inhibiting the cytokine storms. In addition, MSCs have a strong ability to repair tissue damage and reduce the risk of severe complications such as acute lung injury and ARDS, and hopefully, reduce the fatality rate in these patients. There are several clinical types of research completed for treating COVID-19 with MSCs, all reporting restoration of T cells and clinical safety. Here we discuss the clinical prospect and conclude the therapeutic effects and potential mechanism for MSCs in treating COVID-19. Bentham Science Publishers 2020-08 2020-08 /pmc/articles/PMC8388062/ /pubmed/32867652 http://dx.doi.org/10.2174/1566523220999200820172829 Text en © 2020 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Li, Jingwen Wang, Xinyi Li, Na Jiang, Ying Huang, Heqing Wang, Tao Lin, Zhicheng Xiong, Nian Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title | Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title_full | Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title_fullStr | Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title_full_unstemmed | Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title_short | Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review |
title_sort | feasibility of mesenchymal stem cell therapy for covid-19: a mini review |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388062/ https://www.ncbi.nlm.nih.gov/pubmed/32867652 http://dx.doi.org/10.2174/1566523220999200820172829 |
work_keys_str_mv | AT lijingwen feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT wangxinyi feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT lina feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT jiangying feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT huangheqing feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT wangtao feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT linzhicheng feasibilityofmesenchymalstemcelltherapyforcovid19aminireview AT xiongnian feasibilityofmesenchymalstemcelltherapyforcovid19aminireview |